Sign in

NCT04330664CompletedPhase 1

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

A Phase 1/2 Trial of MRTX849 in Combination With TNO155 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL 2

Source: ClinicalTrials.gov · Last updated 4 Apr 2025

Brief summary (registry, in English)

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors that have a KRAS G12C mutation.

Status (registry)
Completed
Phase (registry)
Phase 1
Study type
Interventional
Enrollment
86 (actual)
First submitted
30 Mar 2020
Start date
7 Apr 2020
Primary completion date
29 Jul 2022
Lead sponsor
Mirati Therapeutics Inc.
NCT number
NCT04330664

What you commit to

  • Study type: Interventional · Phase 1
  • Participants enrolled: 86
  • From 7 Apr 2020 to the primary completion date, 29 Jul 2022
  • 17 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of study treatment or result in inability to swallow
  • Other active cancer
  • Cardiac abnormalities

Who the study is looking for

  • Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation (phase 2 must be either Non-Small Cell Lung Cancer or Colorectal Cancer)
  • Unresectable or metastatic disease
  • No available treatment with curative intent
  • Adequate organ function

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (17)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Local Institution - 002-808
Coordinator of this site? Confirm its status
BostonUnited StatesUnknown status
Local Institution - 002-804
Coordinator of this site? Confirm its status
BostonUnited StatesUnknown status
Local Institution - 002-828
Coordinator of this site? Confirm its status
ChicagoUnited StatesUnknown status
Local Institution - 002-809 D
Coordinator of this site? Confirm its status
City of Saint PetersUnited StatesUnknown status
Local Institution - 002-809 B
Coordinator of this site? Confirm its status
Creve CoeurUnited StatesUnknown status
Local Institution - 002-805
Coordinator of this site? Confirm its status
Los AngelesUnited StatesUnknown status
Local Institution - 002-810
Coordinator of this site? Confirm its status
MilwaukeeUnited StatesUnknown status
Local Institution - 002-806
Coordinator of this site? Confirm its status
New YorkUnited StatesUnknown status
Local Institution - 002-813
Coordinator of this site? Confirm its status
New YorkUnited StatesUnknown status
Local Institution - 002-811
Coordinator of this site? Confirm its status
NoviUnited StatesUnknown status
Local Institution - 002-803
Coordinator of this site? Confirm its status
OrangeUnited StatesUnknown status
Local Institution - 002-801
Coordinator of this site? Confirm its status
San AntonioUnited StatesUnknown status
Local Institution - 002-809 E
Coordinator of this site? Confirm its status
St LouisUnited StatesUnknown status
Local Institution - 002-809 A
Coordinator of this site? Confirm its status
St LouisUnited StatesUnknown status
Local Institution - 002-809
Coordinator of this site? Confirm its status
St LouisUnited StatesUnknown status
Local Institution - 002-809 C
Coordinator of this site? Confirm its status
St LouisUnited StatesUnknown status
Local Institution - 002-942
Coordinator of this site? Confirm its status
WichitaUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.